Developer docs
API playgroundTry for free, no card

Search company profiles

Fortress Diagnostics

Full company profile

uuid000erns

Namestring
Fortress Diagnostics
Legal namestring
Fortress Diagnostics
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Fortress Diagnostics is a UK-based in vitro diagnostics (IVD) manufacturer founded in 2000 and headquartered in Antrim, Northern Ireland. The company designs, develops and manufactures clinical diagnostic test kits across clinical chemistry, immunoassay (ELISA and CLIA), molecular diagnostics (RT-qPCR), rapid lateral-flow tests, haematology, haemostasis/coagulation, blood grouping, urinalysis and infectious disease panels (HIV, hepatitis, COVID-19, tuberculosis, syphilis, febrile antigens). Manufacturing is consolidated in a 30,000 sq ft ISO 13485:2016-accredited facility equipped with freeze-drying, specialist manufacturing and automation capabilities, and the portfolio spans more than 1,000 products.

The business sells primarily through an international distributor network covering over 100 countries across five continents, including difficult-to-serve markets such as Libya, Yemen, Iraq, Afghanistan, Haiti and Djibouti. In the UK it supplements distribution with direct sales representatives targeting private hospitals, GPs, clinics, pharmacies and universities, and with channel partners such as Una Health. Revenue streams consist of one-time reagent and consumable sales, instrumentation hardware (the Monarch 240/400/800 clinical chemistry analysers), and lower-volume recurring income from ESfEQA External Quality Assessment subscriptions. R&D intensity is high, with the company reinvesting approximately 30% of annual turnover and maintaining multi-university research partnerships with Queen's University Belfast, University of Nottingham, University of Cape Town and Ulster University.

The company's commercial identity was sharpened by the COVID-19 period: it rapidly launched RT-qPCR, antibody ELISA, IgM/IgG rapid and antigen rapid tests, with the lateral-flow product selected by Imperial College London for the REACT 2 national seroprevalence programme. Fortress has accumulated multiple industry awards including IVD Product Manufacturer of the Year - UK (2024), GHP Best IVD Development and Manufacturing Company (2021) and Belfast Telegraph SME Healthcare Business of the Year (2019), and continues to operate an active global distributor recruitment and product launch programme through 2026.

Short descriptiontext

Fortress Diagnostics is a UK-based in vitro diagnostics manufacturer founded in 2000, producing 1,000+ clinical diagnostic test kits across immunoassay, molecular, rapid and clinical chemistry formats from its ISO 13485-accredited Antrim facility, distributed through a network covering 100+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAntrim, United Kingdom
HQ citystring
Antrim
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, clinical diagnostic test kits, immunoassay reagents, rapid diagnostic tests, clinical chemistry analysers
Industry3 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics (Clinical Diagnostics Manufacturing)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1IVD Reagents and Test Kits
TypeOne Time License
Description

Fortress Diagnostics manufactures and sells an extensive portfolio of clinical diagnostic tests including clinical chemistry reagents, analyser specific reagents, haematology reagents, haemostasis products, immunoassay ELISA and CLIA tests, rapid tests, and molecular diagnostics. Products are sold to laboratories, hospitals, clinics, blood banks and research institutions globally through their distribution network.

fortressdiagnostics.com
2Quality Controls and Calibrators
TypeOne Time License
Description

The company manufactures and sells quality control materials and calibrators for various diagnostic parameters including tumour markers, cardiac markers, diabetes markers, and infectious disease testing to ensure laboratory assay reliability.

fortressdiagnostics.com
3Instrumentation
TypeHardware Sales
Description

Sale of clinical chemistry analysers including the Monarch 240, Monarch 400, and Monarch 800 models for automated random access testing.

fortressdiagnostics.com
4IQC & EQA Programmes
TypeSubscription Recurring
Description

Through partnership with ESfEQA, Fortress offers laboratories participation in internationally recognised External Quality Assessment programs enabling comparison of results with other laboratories.

fortressdiagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom quote-based pricing for all products
ModelOtherBilling cadencePay-as-you-go
Notes

Fortress Diagnostics does not publicly disclose pricing on their website. Customers must contact the company directly for quotes via the 'Check Quote' or 'Send us a Quote' system on their website.

fortressdiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fortress Diagnostics develops, manufactures and supports an extensive portfolio of in vitro diagnostic (IVD) clinical test kits, reagents, quality controls and clinical chemistry analysers from its ISO 13485:2016-accredited facility in the United Kingdom. Its products span ELISA and CLIA immunoassays, rapid point-of-care tests, RT-qPCR molecular diagnostics, clinical chemistry, haematology, haemostasis, blood grouping, serology and urinalysis, and are sold through distributors to hospital laboratories, clinics, blood banks and research institutions in over 100 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98.6%+ accuracy demonstrated for COVID-19 antigen tests
+3 more records
Product overview1 text field

Fortress Diagnostics is an in vitro diagnostics (IVD) company offering an extensive portfolio of clinical diagnostic products manufactured in its ISO 13485:2016-accredited UK facility. The product range includes Clinical Chemistry Reagents and Analyser-Specific Reagents for automated platforms, Controls & Calibrators for quality assurance, Immunoassay ELISA and CLIA tests for protein/hormone/antibody detection, Rapid Tests for point-of-care screening, and Molecular Diagnostics (RT-PCR) for pathogen detection. Key testing categories span Haematology, Haemostasis/Coagulation, Blood Grouping, Urinalysis, Infectious Diseases (HIV, Hepatitis, COVID-19, Tuberculosis), Tumour Markers, and Food & Feed Safety. The company also offers Instrumentation including the Monarch series of clinical chemistry analysers, and supports laboratory quality through IQC & EQA programmes. Products are distributed to over 100 international markets through a global distribution network.

Product and service1 record
1Clinical Chemistry Reagents
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-01
Description

UK distribution partnership for delivery of Fortress Diagnostics COVID-19 products. Una Health is a family-run business with proven track record in customer service and technical support. The partnership enabled delivery of validated COVID-19 tests validated by Porton Down.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Recent R&D partnership announced as part of ongoing collaboration with universities for test development in tuberculosis and cancer diagnostics.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-03-01
Description

Fortress Diagnostics' COVID-19 Rapid Antibody Test was selected as 'the most suitable candidate' for the National Coronavirus Disease 2019 Seroprevalence Programme (REACT 2). The study, funded by the Department of Health and Social Care and commissioned by Imperial College London, is conducted in partnership with Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Foundation Trust. Fortress tests were used for nationwide antibody surveillance across England.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

R&D partnership for joint development of new tests for TB and lung cancer. Development projects completed and manufacturing is underway. TB test already exported to South Africa. University collaboration enables access to research expertise and academic resources.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

R&D partnership for joint development of new tests for TB and lung cancer. Collaboration with African university supports development of diagnostics relevant to regional health priorities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

R&D partnership for development of diagnostic tests including early cancer detection. Proximity to headquarters enables close collaboration with academic researchers in Northern Ireland.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-04-01
Description

Partnership enables Fortress Diagnostics to offer laboratories participation in internationally recognised External Quality Assessment (EQA) programmes. These programmes allow laboratories to compare results with other laboratories to maintain and improve analytical performance quality. Fortress selected the Clinical Chemistry program (31 analytical parameters) and Infectious Disease Program (anti-HIV, anti-HCV, anti-HBc and HBsAg) for the launch, with additional programs available upon request.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Trinity Biotech is a comparable mid-cap IVD company focused on clinical chemistry, haemostasis, infectious-disease ELISA, and point-of-care diagnostics — overlapping with multiple Fortress product lines and a similar scale profile.

TypeBroad incumbent
Description

Roche operates the cobas and Elecsys platforms in immunoassay and clinical chemistry, the dominant global IVD incumbent, and competes with Fortress across reagent menus and analyser placements.

TypeDirect peer
Description

EKF is a UK-headquartered mid-cap IVD company offering point-of-care haemoglobin, HbA1c, and clinical chemistry products, comparable in scale, geography, and channel-distribution profile to Fortress.

TypeDirect peer
Description

Bio-Rad is a global IVD and life-science research company with overlapping portfolios in clinical chemistry quality controls, immunoassays, blood typing reagents, and molecular diagnostics — closely mirroring Fortress's product breadth and laboratory-customer focus.

TypeBroad incumbent
Description

Hologic is a larger diagnostics player with rapid molecular and immunoassay franchises (e.g., Panther, Aptima) that overlap with Fortress's molecular and infectious-disease testing portfolio.

TypeDirect peer
Description

DiaSorin is an Italian-headquartered specialty IVD company focused on CLIA chemiluminescence immunoassays and molecular diagnostics — a tight competitor in the same assay platforms Fortress highlights as differentiators.

TypeDirect peer
Description

SD Biosensor is a global rapid-diagnostics manufacturer with strong emerging-market reach in HIV, malaria, and COVID-19 lateral-flow tests, comparable to Fortress's rapid-test franchise and emerging-market distribution model.

8Abbott Diagnostics
TypeBroad incumbent
Description

Abbott is a global diagnostics incumbent offering Architect/Alinity immunoassay and clinical chemistry systems with extensive reagent menus — overlapping with Fortress's immunoassay and analyser-specific reagent categories.

TypeDirect peer
Description

Headquartered in Northern Ireland (Crumlin, Co. Antrim), Randox is a direct competitor offering an overlapping portfolio of clinical chemistry reagents, immunoassays, quality controls, and infectious-disease IVDs, and shares Fortress's UK-base, export-heavy, multi-discipline IVD business model.

TypeDirect peer
Description

QuidelOrtho specialises in rapid lateral-flow diagnostics and clinical laboratory immunoassays (including infectious disease and women's health), directly comparable to Fortress's rapid-tests and immunoassay ELISA/CLIA franchises.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fortress Diagnostics

In Vitro Diagnostics (Clinical Diagnostics Manufacturing)fortressdiagnostics.com

Fortress Diagnostics is a UK-based in vitro diagnostics manufacturer founded in 2000, producing 1,000+ clinical diagnostic test kits across immunoassay, molecular, rapid and clinical chemistry formats from its ISO 13485-accredited Antrim facility, distributed through a network covering 100+ countries.

What Fortress Diagnostics does

Fortress Diagnostics is a UK-based in vitro diagnostics (IVD) manufacturer founded in 2000 and headquartered in Antrim, Northern Ireland. The company designs, develops and manufactures clinical diagnostic test kits across clinical chemistry, immunoassay (ELISA and CLIA), molecular diagnostics (RT-qPCR), rapid lateral-flow tests, haematology, haemostasis/coagulation, blood grouping, urinalysis and infectious disease panels (HIV, hepatitis, COVID-19, tuberculosis, syphilis, febrile antigens). Manufacturing is consolidated in a 30,000 sq ft ISO 13485:2016-accredited facility equipped with freeze-drying, specialist manufacturing and automation capabilities, and the portfolio spans more than 1,000 products.

The business sells primarily through an international distributor network covering over 100 countries across five continents, including difficult-to-serve markets such as Libya, Yemen, Iraq, Afghanistan, Haiti and Djibouti. In the UK it supplements distribution with direct sales representatives targeting private hospitals, GPs, clinics, pharmacies and universities, and with channel partners such as Una Health. Revenue streams consist of one-time reagent and consumable sales, instrumentation hardware (the Monarch 240/400/800 clinical chemistry analysers), and lower-volume recurring income from ESfEQA External Quality Assessment subscriptions. R&D intensity is high, with the company reinvesting approximately 30% of annual turnover and maintaining multi-university research partnerships with Queen's University Belfast, University of Nottingham, University of Cape Town and Ulster University.

The company's commercial identity was sharpened by the COVID-19 period: it rapidly launched RT-qPCR, antibody ELISA, IgM/IgG rapid and antigen rapid tests, with the lateral-flow product selected by Imperial College London for the REACT 2 national seroprevalence programme. Fortress has accumulated multiple industry awards including IVD Product Manufacturer of the Year - UK (2024), GHP Best IVD Development and Manufacturing Company (2021) and Belfast Telegraph SME Healthcare Business of the Year (2019), and continues to operate an active global distributor recruitment and product launch programme through 2026.

Fortress Diagnostics firmographics

Firmographics
Name
Fortress Diagnostics
Legal name
Fortress Diagnostics
Website
https://fortressdiagnostics.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Fortress Diagnostics is a UK-based in vitro diagnostics manufacturer founded in 2000, producing 1,000+ clinical diagnostic test kits across immunoassay, molecular, rapid and clinical chemistry formats from its ISO 13485-accredited Antrim facility, distributed through a network covering 100+ countries.
Ownership category
akta.pro rank

Fortress Diagnostics industry classification

Industry
Product category
In Vitro Diagnostics (Clinical Diagnostics Manufacturing)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • In vitro diagnostics
  • Clinical diagnostic test kits
  • Immunoassay reagents
  • Rapid diagnostic tests
  • Clinical chemistry analysers

Where Fortress Diagnostics is headquartered

Location

Headquarters

HQ city
Antrim
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Fortress Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. IVD Reagents and Test Kits: Fortress Diagnostics manufactures and sells an extensive portfolio of clinical diagnostic tests including clinical chemistry reagents, analyser specific reagents, haematology reagents, haemostasis products, immunoassay ELISA and CLIA tests, rapid tests, and molecular diagnostics. Products are sold to laboratories, hospitals, clinics, blood banks and research institutions globally through their distribution network.
  2. Quality Controls and Calibrators: The company manufactures and sells quality control materials and calibrators for various diagnostic parameters including tumour markers, cardiac markers, diabetes markers, and infectious disease testing to ensure laboratory assay reliability.
  3. Instrumentation: Sale of clinical chemistry analysers including the Monarch 240, Monarch 400, and Monarch 800 models for automated random access testing.
  4. IQC & EQA Programmes: Through partnership with ESfEQA, Fortress offers laboratories participation in internationally recognised External Quality Assessment programs enabling comparison of results with other laboratories.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCustom quote-based pricing for all products

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Fortress Diagnostics product offering

Product offering

Core offering

Fortress Diagnostics develops, manufactures and supports an extensive portfolio of in vitro diagnostic (IVD) clinical test kits, reagents, quality controls and clinical chemistry analysers from its ISO 13485:2016-accredited facility in the United Kingdom. Its products span ELISA and CLIA immunoassays, rapid point-of-care tests, RT-qPCR molecular diagnostics, clinical chemistry, haematology, haemostasis, blood grouping, serology and urinalysis, and are sold through distributors to hospital laboratories, clinics, blood banks and research institutions in over 100 countries.

Product overview

Fortress Diagnostics is an in vitro diagnostics (IVD) company offering an extensive portfolio of clinical diagnostic products manufactured in its ISO 13485:2016-accredited UK facility. The product range includes Clinical Chemistry Reagents and Analyser-Specific Reagents for automated platforms, Controls & Calibrators for quality assurance, Immunoassay ELISA and CLIA tests for protein/hormone/antibody detection, Rapid Tests for point-of-care screening, and Molecular Diagnostics (RT-PCR) for pathogen detection. Key testing categories span Haematology, Haemostasis/Coagulation, Blood Grouping, Urinalysis, Infectious Diseases (HIV, Hepatitis, COVID-19, Tuberculosis), Tumour Markers, and Food & Feed Safety. The company also offers Instrumentation including the Monarch series of clinical chemistry analysers, and supports laboratory quality through IQC & EQA programmes. Products are distributed to over 100 international markets through a global distribution network.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Chemistry Reagents

Quantifiable outcome

  • 98.6%+ accuracy demonstrated for COVID-19 antigen tests
  • +3 more outcomes

Companies that use Fortress Diagnostics

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Fortress Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Fortress Diagnostics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, minor and flagship.

  • Una HealthcoreChannel Partner/ Reseller/ Distributor · 1 June 2021UK distribution partnership for delivery of Fortress Diagnostics COVID-19 products. Una Health is a family-run business with proven track record in customer service and technical support. The partnership enabled delivery of validated COVID-19 tests validated by Porton Down.
  • Ulster UniversityminorStrategic or Co-development Partner · 1 January 2021Recent R&D partnership announced as part of ongoing collaboration with universities for test development in tuberculosis and cancer diagnostics.
  • Imperial College LondonflagshipStrategic or Co-development Partner · 1 March 2020Fortress Diagnostics' COVID-19 Rapid Antibody Test was selected as 'the most suitable candidate' for the National Coronavirus Disease 2019 Seroprevalence Programme (REACT 2). The study, funded by the Department of Health and Social Care and commissioned by Imperial College London, is conducted in partnership with Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Foundation Trust. Fortress tests were used for nationwide antibody surveillance across England.
  • University of NottinghamcoreStrategic or Co-development Partner · 1 November 2019R&D partnership for joint development of new tests for TB and lung cancer. Development projects completed and manufacturing is underway. TB test already exported to South Africa. University collaboration enables access to research expertise and academic resources.
  • University of Cape TowncoreStrategic or Co-development Partner · 1 November 2019R&D partnership for joint development of new tests for TB and lung cancer. Collaboration with African university supports development of diagnostics relevant to regional health priorities.
  • Queen's University BelfastcoreStrategic or Co-development Partner · 1 November 2019R&D partnership for development of diagnostic tests including early cancer detection. Proximity to headquarters enables close collaboration with academic researchers in Northern Ireland.
  • ESfEQA (European Society for External Quality Assessment)coreStrategic or Co-development Partner · 1 April 2017Partnership enables Fortress Diagnostics to offer laboratories participation in internationally recognised External Quality Assessment (EQA) programmes. These programmes allow laboratories to compare results with other laboratories to maintain and improve analytical performance quality. Fortress selected the Clinical Chemistry program (31 analytical parameters) and Infectious Disease Program (anti-HIV, anti-HCV, anti-HBc and HBsAg) for the launch, with additional programs available upon request.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Fortress Diagnostics competitors and assessment

Company assessment

Direct peers

  • Trinity Biotech: Trinity Biotech is a comparable mid-cap IVD company focused on clinical chemistry, haemostasis, infectious-disease ELISA, and point-of-care diagnostics — overlapping with multiple Fortress product lines and a similar scale profile.
  • EKF Diagnostics: EKF is a UK-headquartered mid-cap IVD company offering point-of-care haemoglobin, HbA1c, and clinical chemistry products, comparable in scale, geography, and channel-distribution profile to Fortress.
  • Bio-Rad Laboratories: Bio-Rad is a global IVD and life-science research company with overlapping portfolios in clinical chemistry quality controls, immunoassays, blood typing reagents, and molecular diagnostics — closely mirroring Fortress's product breadth and laboratory-customer focus.
  • DiaSorin: DiaSorin is an Italian-headquartered specialty IVD company focused on CLIA chemiluminescence immunoassays and molecular diagnostics — a tight competitor in the same assay platforms Fortress highlights as differentiators.
  • SD Biosensor: SD Biosensor is a global rapid-diagnostics manufacturer with strong emerging-market reach in HIV, malaria, and COVID-19 lateral-flow tests, comparable to Fortress's rapid-test franchise and emerging-market distribution model.
  • Randox Laboratories: Headquartered in Northern Ireland (Crumlin, Co. Antrim), Randox is a direct competitor offering an overlapping portfolio of clinical chemistry reagents, immunoassays, quality controls, and infectious-disease IVDs, and shares Fortress's UK-base, export-heavy, multi-discipline IVD business model.
  • QuidelOrtho: QuidelOrtho specialises in rapid lateral-flow diagnostics and clinical laboratory immunoassays (including infectious disease and women's health), directly comparable to Fortress's rapid-tests and immunoassay ELISA/CLIA franchises.

Broad incumbents

  • Roche Diagnostics: Roche operates the cobas and Elecsys platforms in immunoassay and clinical chemistry, the dominant global IVD incumbent, and competes with Fortress across reagent menus and analyser placements.
  • Hologic: Hologic is a larger diagnostics player with rapid molecular and immunoassay franchises (e.g., Panther, Aptima) that overlap with Fortress's molecular and infectious-disease testing portfolio.
  • Abbott Diagnostics: Abbott is a global diagnostics incumbent offering Architect/Alinity immunoassay and clinical chemistry systems with extensive reagent menus — overlapping with Fortress's immunoassay and analyser-specific reagent categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Fortress Diagnostics social profiles

Digital presence

Fortress Diagnostics compliance and trust

Trust signal

Compliance6 records

Fortress Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fortress Diagnostics leadership team

Management profile

Number of profiles

Profiles3 records

Fortress Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fortress Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fortress Diagnostics

What does Fortress Diagnostics do?

Fortress Diagnostics develops, manufactures and supports an extensive portfolio of in vitro diagnostic (IVD) clinical test kits, reagents, quality controls and clinical chemistry analysers from its ISO 13485:2016-accredited facility in the United Kingdom. Its products span ELISA and CLIA immunoassays, rapid point-of-care tests, RT-qPCR molecular diagnostics, clinical chemistry, haematology, haemostasis, blood grouping, serology and urinalysis, and are sold through distributors to hospital laboratories, clinics, blood banks and research institutions in over 100 countries.

Is Fortress Diagnostics a public or private company?

Fortress Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Fortress Diagnostics founded?

Fortress Diagnostics was founded in 2000. It employs 11 to 50 people.

Where is Fortress Diagnostics based?

Fortress Diagnostics is headquartered in Antrim, United Kingdom, in the Europe region.

How does Fortress Diagnostics make money?

Four revenue lines are on record. IVD Reagents and Test Kits are the primary driver. The others are quality Controls and Calibrators, instrumentation and IQC & EQA Programmes.

Who are Fortress Diagnostics's main competitors?

Direct peers on record are Trinity Biotech, EKF Diagnostics, Bio-Rad Laboratories, DiaSorin, SD Biosensor, Randox Laboratories and QuidelOrtho. Broad incumbents are Roche Diagnostics, Hologic and Abbott Diagnostics.

Does Fortress Diagnostics have an API?

No public API is recorded for Fortress Diagnostics.

What industry is Fortress Diagnostics in?

Fortress Diagnostics's product category is In Vitro Diagnostics (Clinical Diagnostics Manufacturing). Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales